Dr. James Youssef, MD
Heart Failure & Transplant Cardiology (Advanced Heart Failure and Transplant Cardiology Physician)
- Medicare participating
At a glance
- Years since graduation
- 17
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 261
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Advanced Heart Failure and Transplant Cardiology Physician primary
NY license 272255 -
Cardiovascular Disease Physician
NY license 272255 -
Internal Medicine Physician
NY license 272255
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: Heart Failure & Transplant Cardiology per capita by county →
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
- Kaleida Health Buffalo, NY
- Mount Sinai West New York, NY
- Mount Sinai Beth Israel New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
- General Physician PC (501 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 261
- Services billed
- 584
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 100 | 39 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 76 | 30 |
| Established patient office or other outpatient visit, 30-39 minutes | 53 | 48 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 29 | 29 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 28 | 28 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | 26 | 26 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | 26 | 26 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 26 | 26 |
| Ct scan of heart structure with contrast | 25 | 25 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 21 | 20 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Entresto (sacubitril/valsartan) Other prescribers in New York, NY | 47 |
| Metoprolol Succinate Other prescribers in New York, NY | 39 |
| Spironolactone Other prescribers in New York, NY | 36 |
| Vyndamax (tafamidis) | 27 |
| Furosemide Other prescribers in New York, NY | 27 |
| Eliquis (apixaban) Other prescribers in New York, NY | 27 |
| Farxiga (dapagliflozin propanediol) Other prescribers in New York, NY | 24 |
| Carvedilol Other prescribers in New York, NY | 23 |
| Jardiance (empagliflozin) Other prescribers in New York, NY | 22 |
| Atorvastatin Calcium Other prescribers in New York, NY | 18 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 11 companies reported 36 payments worth $4,614 in total to this clinician.
| Alnylam Pharmaceuticals Inc. | $3,496 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $391 |
| Abbott Laboratories | $217 |
| Bridgebio Pharma, Inc. | $193 |
| Abiomed | $112 |
| Pfizer Inc. | $54.80 |
| Becton, Dickinson and Company | $42.30 |
| Heartflow, Inc. | $42.03 |
| Consulting Fee | $3,000 |
|---|---|
| Food and Beverage | $1,614 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alnylam Pharmaceuticals Inc. Oct 14, 2025 | Consulting Fee AMVUTTRA · Genetic Disease | $3,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $124,097 in research payments for these studies, mostly to the institutions running them.
- APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.